tiprankstipranks
Trending News
More News >
OncoZenge AB (DE:8LY)
FRANKFURT:8LY
Germany Market

OncoZenge AB (8LY) Income Statement

Compare
0 Followers

OncoZenge AB Income Statement

Last quarter (Q4 2024), OncoZenge AB's total revenue was kr0.00, a decrease of -100.00% from the same quarter last year. In Q4, OncoZenge AB's net income was kr-2.50M. See OncoZenge AB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20
Total Revenue
kr 3.00Kkr 0.00kr 0.00kr 0.00
Gross Profit
kr 3.00Kkr 0.00kr 0.00kr 0.00
Operating Expenses
kr 15.90Mkr 43.57Mkr 4.89Mkr 801.00K
Depreciation and Amortization
kr 23.17Mkr 23.17Mkr 236.56Kkr 801.00K
EBITDA
kr 7.27Mkr -43.57Mkr -4.89Mkr -801.00K
Operating Income
kr -15.90Mkr -43.57Mkr -4.89Mkr -801.00K
Other Income/Expenses
kr 0.00kr 0.00kr 0.00kr 0.00
Pretax Income
kr -15.90Mkr -43.57Mkr -4.89Mkr -801.00K
Net Income
kr -15.90Mkr -46.65Mkr -3.89Mkr -636.00K
Per Share Metrics
Basic EPS
kr -1.36kr -3.98kr -0.33kr -0.04
Diluted EPS
kr -1.36kr -3.98kr -0.33kr -0.04
Weighted Average Shares Outstanding
11.71M 11.71M 11.71M 14.55M
Weighted Average Shares Outstanding (Diluted)
11.71M 11.71M 11.71M 14.55M
Currency in SEK

OncoZenge AB Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis